Actinium Pharmaceuticals will showcase ATNM-400's preclinical efficacy in therapy-resistant breast cancer at the upcoming SABCS 2026, emphasizing its potential across various cancers.

Actinium Pharmaceuticals announces significant findings from ASH 2026, revealing Iomab-ACT's promise in CAR T-cell therapy and sickle cell disease treatment.

Actinium Pharmaceuticals has announced new long-term results for Actimab-A combined with CLAG-M in patients with relapsed or refractory AML, showcasing its safety and potential effectiveness.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Actinium Pharmaceuticals has announced an inducement equity award to a new non-executive employee, encouraging talent while enhancing its growth strategy in targeted radiotherapies.

Monte Carlo simulations show that alpha particles from the actinium-225 decay chain dominate tumor dose delivery and that retaining bismuth-213 within the tumor is critical, with actinium-225

Actinium Pharmaceuticals (ATNM) announced an ASH 2026 abstract evaluating long-term safety of Actimab-A plus CLAG-M chemotherapy in relapsed or refractory acute myeloid leukemia.The Phase 1 follow-up examines blood count recovery and potential delayed kidney and liver toxicities among patients who survived at least three months after treatment. Previously presented ASH 2022 data reported estimated one-year and two-year overall survival of 59% and 32% in patients previously treated with venetoclax, and 51% and 19% in patients with TP53-mutated disease. Actinium said the findings support further evaluation of Actimab-A as a potential treatment backbone across mutations in CD33-positive AML. The poster is scheduled for December 13, 2026.

Actinium Pharmaceuticals (ATNM) granted a newly hired non-executive employee an option to purchase 3,000 common shares on October 26, 2026.The option has a $1.40 exercise price, equal to the stock's closing price that day, and a ten-year term. Of the underlying shares, 28% vest on the grant's first anniversary; the remainder vest in monthly installments of 2% over the following 36 months. Vesting requires continued service through each applicable date. The employment inducement award was granted outside the Amended and Restated 2019 Stock Plan under the 2026 Employment Inducement Award Plan.

Belgoprocess, dat in Dessel radioactief afval verwerkt, zal het radium zuiveren waarmee de nucleaire start-up Pantera in Mol straks op grote schaal actinium-225 wil produceren, een onderdeel van een p...

Belgoprocess, dat in Dessel radioactief afval verwerkt, zal het radium zuiveren waarmee de nucleaire start-up Pantera in Mol straks op grote schaal actinium-225 wil produceren, een onderdeel van een p...

IAEA strengthens global collaboration to advance actinium-225 radiopharmaceuticals and bring targeted cancer therapies closer to patients.

Actinium Pharmaceuticals (ATNM) will feature its first-in-human Phase 1 study of ATNM-400 at ESMO 2026, held October 23–27 in Madrid. The investigational radiotherapy targets HER3 rather than PSMA in metastatic castration-resistant prostate cancer, disease that has spread and resists testosterone-lowering treatment.The study combines Zirconium-89-labeled imaging with Actinium-225 treatment to assess safety and establish a recommended Phase 2 dose. Patients with positive imaging proceed to treatment every six weeks for up to four cycles. Enrollment includes patients with and without prior PSMA-directed therapy. Initial imaging results showed tumor uptake and retention through Day 7; the company described initial tolerability as encouraging. The ESMO presentation is a trial-in-progress ePoster, with additional study assessments covering radiation exposure, drug behavior in the body and antitumor activity.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced en...

Actinium Pharmaceuticals has unveiled promising preclinical results for ATNM-400 at EANM 2026, highlighting its effectiveness across various cancers.

Actinium Pharmaceuticals showcased promising results for ATNM-400, a novel HER3-targeted radiotherapy, showing strong initial safety and efficacy data in prostate cancer treatment at EANM 2026.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced ne...

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.